Arvinas Puts a 30% Bar on Its Own Comeback Story

One-time revenue flattered the P&L, expenses are down a quarter, and a $458M market cap now hangs on December BCL6 data management is deliberately underselling.

ARVN · Earnings Call · 2026-11-03

A Bar Set Low Enough to Clear

Randy Teel has spent a year telling investors Arvinas will only fund programs that can be differentiated. On the Q3 call that philosophy met a hard calendar: the first clinical look at ARV-393, an oral degrader aimed at BCL6, a transcription factor once considered classically undruggable, lands at ASH in December. And management pre-set the goalposts unusually low.

With therapies on the market getting something like 35% to 45% in a first-dose escalation study with low doses like we are in now, we and the investigators would be pretty excited with anything over really a 30% response rate.
Randy Teel, President and CEO · 2026-11-03

The honesty is refreshing, and the subtext is unmistakable. On the same call Teel conceded the competition: “patients on a monotherapy BCL6 de grader, which you have seen some other players, have had response rates of over 50%.” — Randy Teel, President and CEO · 2026-11-03 The December cut focuses deliberately on T-cell lymphomas because the B-cell numbers are not yet readable; most patients were dosed below predicted efficacious exposures. That is the low starting dose problem the company has nursed for quarters. Back in August, Teel admitted Arvinas "got some feedback to start with a very low starting dose for BCL6 as monotherapy," and even then claimed to have “seen some early responses in both the B and T-cell lymphomas.” — Randy Teel, President and CEO · 2026-05-12 The fuller B-cell read, plus the eagerly anticipated glofi combo data with glofitamab, is now pushed to mid-2027. Analyst Li Watsek was guided to expect "mid-teens or so" T-cell patients in December, at the shortest follow-up. This is a first look, not a verdict.

The Accounting Ghost and the Lean Pivot

Strip out the accounting and Arvinas looks almost profitable on paper. The fundamentals show Total Revenue of $250M in the June quarter and Operating Income of $170M. Neither is recurring. That revenue is the Pfizer collaboration being pulled forward, which Andrew Saik flagged a quarter earlier:

we took all of the residual collaboration revenue through the P&L. So going forward, you'll see no additional revenue recognition.
Andrew Saik, Chief Financial Officer · 2026-08-04

Which makes the Price to Revenue multiple of 1.7x an optical illusion rather than a valuation signal. The actual Q3 top line was a single $0.5M first royalty from Rigel — the new, thin revenue model in miniature. The genuine change is on the cost side. Non-GAAP expenses fell 25% year over year, and Research And Development was $53M, down 23%, with G&A nearly halved. That discipline buys time: “we had $558.9 million in cash equivalents, restricted cash, and marketable securities on the balance sheet” — Andrew Saik, Chief Financial Officer · 2026-11-03, a runway management extends into the second half of 2028. For perspective, Effective Net Cash has bled from $4.3B in late 2021 to about $1B. The company is spending the last of its late-stage war chest to buy shots on goal.

The Hold That Won't Quit

The LRRK2 neurosciences program remains the sorest spot. The U.S. clinical hold has not lifted, and Teel was blunt: “investors should assume that the phase I-B will begin without U.S. patients, but that is not to say that later in the development plan we could not bring the U.S. back in.” — Randy Teel, President and CEO · 2026-11-03 The company has pivoted to a European and U.K. CTA process, with the PSP trial targeted for 2027 — a geographic workaround that analysts have now probed for three straight calls. The scientific case remains that a degrader hits all three LRRK2 functions where Denali/Biogen's inhibitor (which failed) touched only kinase. But the regulatory overhang is old and unresolved, and the program's keyword momentum has visibly decayed even as it keeps slipping in the timeline.

The IO Bet and the Market's Checkpoint Wave

What is genuinely new for Arvinas is immuno-oncology. The freshest top-ranked keyword this quarter is checkpoint inhibitor, reflecting ARV-6723, the company's first IO asset and its first HPK1 degrader. The strategy is to enroll entirely post-checkpoint patients, a population where prior HPK1 inhibitors have largely failed, aiming at a different axis of the immune cascade. That theme is not company-unique — Immune checkpoint inhibitors sit among the market tape's 90-day advancers and the theme threads through ABBV and MRK earnings — but the payoff is distant: first data guided to the second half of 2027. The quieter option is SBMA patients, where ARV-027 targets the polyQ androgen receptor driving Kennedy's disease. Arvinas is chasing a ~50% muscle degradation threshold it believes rescued strength and endurance in mice, with healthy-volunteer and patient data slated for the first half of 2027.

Bottom Line

Arvinas is a $458M market cap trading 26% below its August high, still 93% below its 2021 peak, and now priced almost entirely on a December BCL6 readout that management has pre-framed as a low bar. The real story is a company that has quietly converted from a late-stage vepdegestrant bet into a lean, cash-disciplined, early-stage option on protein degradation — with a real IO program arriving too late to matter for the current quote. In December the data either clears a modest 30% hurdle or it does not; everything else is 2027.